Comparison of KRAS mutation status between primary tumor and metastasis in Chinese colorectal cancer patients
- 450 Downloads
Detection of KRAS mutation status is a routine clinical procedure for predicting response to anti-EGFR therapy in colorectal cancer (CRC) patients. Previous studies showed high concordance of KRAS mutation status in primary lesion and corresponding metastatic sites in CRC. However, the data were mostly from Caucasians. The aim of this study is to compare KRAS mutation and other molecules mutation status between primary tumor and corresponding metastatic lesion in Chinese patients with CRC. In this retrospective study, Chinese CRC patients with paired samples of primary tumor and metastatic site were detected for KRAS codon 12 and 13 with quantitative real-time PCR, or detected for OncoCarta™ panel of 19 genes with MassARRAY® technique, including KRAS, BRAF, NRAS and PIK3CA et al. Forty-eight paired CRC samples were analyzed for KRAS codon 12 and 13 using quantitative real-time PCR. Ten paired samples were analyzed by 19 genes OncoCarta™ Panel with MassARRAY® technique. KRAS mutation was found in 15 (25.9 %) primary tumors and 18 (31.0 %) metastases. The discordance of KRAS was observed in 11 (19.0 %) patients. Alteration of mutation points in primary site with mutant KRAS was not observed. In the 10 patients with multiple gene detection, PIK3CA mutation showed concordant mutation status in primary tumor and metastatic site, whereas discordance in BRAF, NRAS and AKT1 was detected. A concordance rate of 81.0 % was detected in KRAS mutation between primary tumor and metastatic lesion in Chinese patients with CRC. Discordance of BRAF, NRAS and AKT1 mutation status in primary tumor and metastases was observed.
KeywordsColorectal cancer KRAS mutation Primary tumor Metastases Concordance
This work was supported by The National Natural Science Foundation of China (No. 81372570), the Science and Technology Department of Guangdong Province, China (No. 2012B031800088) and the Science and Technology Department of Guangdong Province, China (No. C2011019). The authors gratefully thank staff members in the Department of Medical Oncology and Department of Molecular Diagnostics at Sun Yat-sen University Cancer Center for their suggestions and assistance.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
Informed consent was obtained from all individual participants included in the study, giving their authorization to access their clinical information and tumor samples for research purpose.
- 4.Edge SB, BDCC, American Joint Committee on Cancer (AJCC). Cancer staging manual. 7th ed. New York: Springer; 2010.Google Scholar
- 6.Wasan H, Meade AM, Adams R, Wilson R, Pugh C, Fisher D, et al. Intermittent chemotherapy plus either intermittent or continuous cetuximab for first-line treatment of patients with KRAS wild-type advanced colorectal cancer (COIN-B): a randomised phase 2 trial. Lancet Oncol. 2014;15(6):631–9. doi: 10.1016/S1470-2045(14)70106-8.CrossRefPubMedPubMedCentralGoogle Scholar
- 7.Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, et al. Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer. Ann Oncol. 2014;25(7):1346–55. doi: 10.1093/annonc/mdu141.CrossRefPubMedGoogle Scholar
- 9.Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol. 2007;25(13):1658–64. doi: 10.1200/JCO.2006.08.1620.CrossRefPubMedGoogle Scholar
- 12.Allegra CJ, Rumble RB, Hamilton SR, Mangu PB, Roach N, Hantel A, et al. Extended RAS gene mutation testing in metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015. J Clin Oncol. 2016;34(2):179–85. doi: 10.1200/JCO.2015.63.9674.CrossRefPubMedGoogle Scholar
- 13.NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Colon cancer [version 2. 2016]. 2015; 2015(30 Nov).Google Scholar
- 15.Harle A, Salleron J, Perkins G, Pilati C, Blons H, Laurent-Puig P, et al. Expression of pEGFR and pAKT as response-predictive biomarkers for RAS wild-type patients to anti-EGFR monoclonal antibodies in metastatic colorectal cancers. Br J Cancer. 2015;113(4):680–5. doi: 10.1038/bjc.2015.250.CrossRefPubMedGoogle Scholar
- 17.Tian S, Simon I, Moreno V, Roepman P, Tabernero J, Snel M, et al. A combined oncogenic pathway signature of BRAF, KRAS and PI3KCA mutation improves colorectal cancer classification and cetuximab treatment prediction. Gut. 2013;62(4):540–9. doi: 10.1136/gutjnl-2012-302423.CrossRefPubMedGoogle Scholar
- 18.De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 2010;11(8):753–62. doi: 10.1016/S1470-2045(10)70130-3.CrossRefPubMedGoogle Scholar
- 25.Sun L, Zhang Q, Luan H, Zhan Z, Wang C, Sun B. Comparison of KRAS and EGFR gene status between primary non-small cell lung cancer and local lymph node metastases: implications for clinical practice. J Exp Clin Cancer Res. 2011;30:30. doi: 10.1186/1756-9966-30-30.CrossRefPubMedPubMedCentralGoogle Scholar
- 26.Curtit E, Nerich V, Mansi L, Chaigneau L, Cals L, Villanueva C, et al. Discordances in estrogen receptor status, progesterone receptor status, and HER2 status between primary breast cancer and metastasis. Oncologist. 2013;18(6):667–74. doi: 10.1634/theoncologist.2012-0350.CrossRefPubMedPubMedCentralGoogle Scholar
- 29.Etienne-Grimaldi MC, Formento JL, Francoual M, Francois E, Formento P, Renee N, et al. K-Ras mutations and treatment outcome in colorectal cancer patients receiving exclusive fluoropyrimidine therapy. Clin Cancer Res. 2008;14(15):4830–5. doi: 10.1158/1078-0432.CCR-07-4906.CrossRefPubMedGoogle Scholar
- 30.Park JH, Han SW, Oh DY, Im SA, Jeong SY, Park KJ, et al. Analysis of KRAS, BRAF, PTEN, IGF1R, EGFR intron 1 CA status in both primary tumors and paired metastases in determining benefit from cetuximab therapy in colon cancer. Cancer Chemother Pharmacol. 2011;68(4):1045–55. doi: 10.1007/s00280-011-1586-z.CrossRefPubMedGoogle Scholar
- 31.Baldus SE, Schaefer KL, Engers R, Hartleb D, Stoecklein NH, Gabbert HE. Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases. Clin Cancer Res. 2010;16(3):790–9. doi: 10.1158/1078-0432.CCR-09-2446.CrossRefPubMedGoogle Scholar
- 32.Sequenom MassARRAY System Brochure.Google Scholar
- 33.OncoCarta Panel v1.0 Flyer.Google Scholar
- 34.Watanabe T, Kobunai T, Yamamoto Y, Matsuda K, Ishihara S, Nozawa K, et al. Heterogeneity of KRAS status may explain the subset of discordant KRAS status between primary and metastatic colorectal cancer. Dis Colon Rectum. 2011;54(9):1170–8. doi: 10.1097/DCR.0b013e31821d37a3.CrossRefPubMedGoogle Scholar
- 35.Knijn N, Mekenkamp LJ, Klomp M, Vink-Borger ME, Tol J, Teerenstra S, et al. KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients. Br J Cancer. 2011;104(6):1020–6. doi: 10.1038/bjc.2011.26.CrossRefPubMedPubMedCentralGoogle Scholar
- 36.Cejas P, Lopez-Gomez M, Aguayo C, Madero R, de Castro Carpeno J, Belda-Iniesta C, et al. KRAS mutations in primary colorectal cancer tumors and related metastases: a potential role in prediction of lung metastasis. PLoS ONE. 2009;4(12):e8199. doi: 10.1371/journal.pone.0008199.CrossRefPubMedPubMedCentralGoogle Scholar
- 37.Santini D, Loupakis F, Vincenzi B, Floriani I, Stasi I, Canestrari E, et al. High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice. Oncologist. 2008;13(12):1270–5. doi: 10.1634/theoncologist.2008-0181.CrossRefPubMedGoogle Scholar
- 38.Kim MJ, Lee HS, Kim JH, Kim YJ, Kwon JH, Lee JO, et al. Different metastatic pattern according to the KRAS mutational status and site-specific discordance of KRAS status in patients with colorectal cancer. BMC Cancer. 2012;12:347. doi: 10.1186/1471-2407-12-347.CrossRefPubMedPubMedCentralGoogle Scholar
- 40.Albanese I, Scibetta AG, Migliavacca M, Russo A, Bazan V, Tomasino RM, et al. Heterogeneity within and between primary colorectal carcinomas and matched metastases as revealed by analysis of Ki-ras and p53 mutations. Biochem Biophys Res Commun. 2004;325(3):784–91. doi: 10.1016/j.bbrc.2004.10.111.CrossRefPubMedGoogle Scholar
- 44.Pietrantonio F, Petrelli F, Coinu A, Di Bartolomeo M, Borgonovo K, Maggi C, et al. Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis. Eur J Cancer. 2015;51(5):587–94. doi: 10.1016/j.ejca.2015.01.054.CrossRefPubMedGoogle Scholar
- 48.Bouchahda M, Karaboue A, Saffroy R, Innominato P, Gorden L, Guettier C, et al. Acquired KRAS mutations during progression of colorectal cancer metastases: possible implications for therapy and prognosis. Cancer Chemother Pharmacol. 2010;66(3):605–9. doi: 10.1007/s00280-010-1298-9.CrossRefPubMedGoogle Scholar